The Pharmacy Times® Cervical Cancer Resource Center is a comprehensive resource for clinical news and expert insights for the type of cancer that occurs in the cells of the cervix.
February 23rd 2023
Including the ThinPrep Pap Test improves access to the benefits of the human papillomavirus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually.
January 10th 2023
September 28th 2022
Study: Spike in New Annual Cases of Advanced Cervical Cancer Seen Among White Women Less Likely to Have HPV VaccineAugust 25th 2022
Overall rates of early-stage cervical cancer in the United States have been falling, but cases with advanced disease are continuing to rise.
Cases of HPV-Linked Cancers Increase in Parts of United States With High Smoking RatesMarch 15th 2022
The research team used the National Cancer Institute’s Surveillance, Epidemiology, and End Results database, which provides nationwide information on cancer statistics.
Roche’s CINtec PLUS Cytology Test Beneficial for Women at Higher Risk of Developing Cervical CancerNovember 16th 2021
In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine whether their cervical cells were transforming to cervical pre-cancer.
FDA Approves Tisotumab Vedotin-tftv for Previously Treated Recurrent, Metastatic Cervical CancerSeptember 21st 2021
Trial results showed a 24% confirmed objective response rate with a median duration of response of 8.3 months among patients with cervical cancer who received tisotumab vedotin-tftv.
Combination Therapy of Pembrolizumab and Chemotherapy Proves Effective Against Certain Cervical CancersJune 23rd 2021
According to the authors of the KEYNOTE-826 trial results, this is the first anti-programmed death receptor-1 (PD-1)/PD-L1 therapy to demonstrate improvements in OS and PFS that were clinically meaningful and statistically significant regardless of PD-L1 status.
Phase 3 Trial of Cemiplimab Shows Promise in Advanced Cervical CancerMay 17th 2021
The trial found positive results in both the overall study population of patients with advanced cervical cancer as well as subgroups with squamous cell carcinoma and adenocarcinoma.
Phase 3 Trial of Cemiplimab Monotherapy in Advanced Cervical Cancer Stopped Early Due to Positive Survival ResultsMarch 24th 2021
Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
Biomarkers Predict Response to Treatment in Cervical and Endometrial CancersFebruary 24th 2021
In a live virtual symposium presented at the 2020 ASHP Midyear Clinical Meeting and Exhibition, Allison Baxley, PharmD, BCOP, and Laura Alwan, PharmD, BCOP, engaged pharmacists in learning about the role of biomarkers in cervical and endometrial cancers.
FDA to Evaluate Tisotumab Vedotin in Recurrent or Metastatic Cervical CancerFebruary 11th 2021
A biologics license application has been submitted to the FDA for the accelerated approval of tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.
Biologics License Application for Bevacizumab Biosimilar BAT1706January 29th 2021
If approved, the biosimilar will be indicated for use in metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.
Researchers Conduct First-of-Its-Kind Review of National Data, HPV Vaccination RatesJanuary 26th 2021
HPV is the most common sexually transmitted infection, and if a high-risk infection does not go away, it can lead to the development of a variety of cancers, including 91% of all cervical cancers, 70% of oropharyngeal cancers, and cancers of the vulva, vagina, and penis and anus.
Managing Therapies in Patients With Cervical and Endometrial CancersJanuary 5th 2021
Pharmacists play a key role in educating patients on risk factors for cervical and endometrial cancers and can assist with treatment decisions, and management of potential adverse effects in patients with these cancers.
No Survival Improvement From Radical Hysterectomy in Patients With Cervical Cancer, Intraoperative Detection of Positive Lymph Node InvolvementSeptember 25th 2020
Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.